Add BrightSurf on Google Email

MIT IDs link between brain tumor proteins

MIT scientists have discovered a connection between two proteins found in brain tumors that could help treat glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Attacking both EGFRvIII and c-Met simultaneously is more effective than targeting either protein alone, offering new hope for treating this deadly disease.

SourceMassachusetts Institute of Technology·JournalProceedings of the National Academy of Sciences·DateJul 19, 2007

Innovative device to treat brain cancer shows promise in early studies

The Novo-TTF device has been shown to disrupt tumor growth by interfering with cell division of cancerous cells, causing them to stop proliferating and die off. In a pilot trial, 10 patients with recurring GBM experienced improved survival rates, with median overall survival doubling compared to historical data.

SourceEdelman Public Relations, New York·JournalProceedings of the National Academy of Sciences·DateMay 29, 2007

Novel EGFR ectodomain mutations in glioblastoma

Researchers have discovered a new class of genetic mutations in the EGFR gene that occur in glioblastoma, a deadly type of brain tumor. These mutations, located in the extracellular domain of the protein, can activate oncogenically EGFR, making them a potential target for cancer therapy.

SourcePLOS·JournalPLOS Medicine·DateDec 18, 2006

Researchers identify target for therapeutic drugs to fight most common adult brain cancer

Glioblastoma multiforme, the most common adult brain cancer, has a median survival of about one year after diagnosis. Researchers have identified EGFR as a target for therapeutic drugs, offering new hope for patients. The study found that targeting both mutant and normal EGFR can destroy brain cancer cells while sparing healthy ones.

SourceUT Southwestern Medical Center·JournalCancer Research·DateJan 15, 2006

Research detects mechanism that appears to enable deadly brain tumors to progress, develop blood supplies to fuel their growth, and invade neighboring healthy tissues

Scientists at Cedars-Sinai Medical Center used gene array technology to analyze thousands of genes in malignant brain tumor samples. They identified a critical step in the development of glioblastoma multiforme, which may improve patient prognosis and lead to effective therapies.

SourceCedars-Sinai Medical Center·JournalCancer Research·DateJul 14, 2001

Marker Found For The Most Malignant Brain Tumors

Researchers at Penn State's College of Medicine have identified a marker for certain types of brain tumors, including glioblastoma multiforme (GBM), which are the most prevalent and difficult-to-manage. The marker, interleukin 13 receptor, is present in over 90% of patients with GBM, making it a valuable diagnostic tool.

SourcePenn State·JournalClinical Cancer Research·DateMay 10, 1999